Posted 31 January, 2024

FibroBiologics Inc. IPO completed

IPO completed detected for ticker Nasdaq:FBLG in a 424B4 filed on 31 January, 2024.

  This is not an underwritten initial public offering of common stock.  

Don't know how to trade IPO completion? Read Initial Public Offerings.
Overview of FibroBiologics Inc.
Health Care/Life Sciences • Biotechnology
FibroBiologics, Inc. engages in the development and commercialization of cell therapies. It focuses on treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. The firm’s product pipeline includes CybroCell, CYMS101, CYWC628, TCB190, and CYTER915. The company was founded by Peter O’Heeron on April 8, 2021 and is headquartered in Houston, TX.
Market Cap
View Company Details